Financing ·
On July 23, 2026, Matinas BioPharma Holdings, Inc. announced the immediate termination of its $50,000,000…
MTNBMatinas BioPharma Holdings, Inc.
On July 23, 2026, Matinas BioPharma Holdings, Inc. announced the immediate termination of its $50,000,000 At-The-Market Sales Agreement with BTIG, LLC, which was originally entered into on July 2, 2020. The company is not subject to any termination penalties or expenses. Matinas BioPharma Holdings, Inc. is a biopharmaceutical company focused on its proprietary LNP-RNA platform.</div>